Arena Pharmaceuticals Inc (ARNA)

20.53
NASDAQ : Health Care
Prev Close 20.58
Day Low/High 20.36 / 21.00
52 Wk Low/High 11.30 / 27.86
Avg Volume 1.11M
Exchange NASDAQ
Shares Outstanding 39.22M
Market Cap 807.15M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Former hedge funder and biotech CEO Martin Shkreli finds himself in limbo as a criminal jury now decides if allegations of fraud will put him in orange coveralls.

Arena Pharma Skyrockets on Heart Disease Data, Stock Could Still Double -Firm Says

Arena Pharma Skyrockets on Heart Disease Data, Stock Could Still Double -Firm Says

The company just beat a bench mark, previously set by Johnson & Johnson.

Xilinx, Arena Pharmaceuticals, Magellan Midstream: 'Mad Money' Lightning Round

Xilinx, Arena Pharmaceuticals, Magellan Midstream: 'Mad Money' Lightning Round

Jim Cramer is bullish on Xilinx, Arena Pharmaceuticals, Magellan Midstream, Altria and Bank of Montreal.

'I Love the Down-and-Outers': Cramer's 'Mad Money' Recap (Thursday 7/13/17)

'I Love the Down-and-Outers': Cramer's 'Mad Money' Recap (Thursday 7/13/17)

Cramer says it's the sign of a good market: Investors are finding value in the stocks that were left behind.

This $3 Biotech Stock Is Making an 11% Move Thursday

This $3 Biotech Stock Is Making an 11% Move Thursday

In focus.

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Big gains could be ahead for investors willing to stick with the stock, according to one firm.

Arena Pharmaceuticals Reports Positive Topline Phase 2 Results For Ralinepag In Patients With Pulmonary Arterial Hypertension

Arena Pharmaceuticals Reports Positive Topline Phase 2 Results For Ralinepag In Patients With Pulmonary Arterial Hypertension

- Primary efficacy analysis successful - significant improvement in pulmonary vascular resistance

Biotech Movers: Alexion, Arena, Novavax

Biotech Movers: Alexion, Arena, Novavax

Alexion, Arena and Novavax were among the biotech stock movers ahead of the market open on Friday, July 7.

Citi Sees This Drug Maker's Stock Soaring 53% Because of What It's Working On

Citi Sees This Drug Maker's Stock Soaring 53% Because of What It's Working On

Citi initiated Arena with a 'buy' rating.

Here Comes a Big Breakout For Alibaba

Here Comes a Big Breakout For Alibaba

What the charts say.

Commit To Buy Arena Pharmaceuticals At $1, Earn 41.4% Annualized Using Options

Investors considering a purchase of Arena Pharmaceuticals Inc shares, but tentative about paying the going market price of $1.35/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $1 strike, which has a bid at the time of this writing of 27 cents.

Arena Pharmaceuticals To Host Key Opinion Leader Event On Pulmonary Arterial Hypertension (PAH) On May 25 In New York City

- Lewis Rubin, M.D. and Vallerie McLaughlin, M.D. to Present

Biotech Movers: Pacific Biosciences Falls After Net Loss Spikes

Biotech Movers: Pacific Biosciences Falls After Net Loss Spikes

Pacific Biosciences of California, Alexion Pharmaceuticals and Arena Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.

Arena Takes a Beating After Lackluster Secondary, Cytokinetics Pops: Biotech Movers

Arena Takes a Beating After Lackluster Secondary, Cytokinetics Pops: Biotech Movers

Arena Pharmaceuticals, Rigel Pharmaceuticals and Cytokinetics were among the biotech stock movers in premarket trading on Tuesday.

Arena Pharmaceuticals Announces Multiple Presentations At ASPET 2017 At Experimental Biology

- Data to highlight etrasimod, Arena's orally available next generation sphingosine-1-phosphate (S1P) receptor modulator for the potential treatment of autoimmune diseases -